TTS 2018 is now considering abstracts in the late-breaker and poster categories until FEBRUARY 15.

It is anticipated that the compilation of late breaker abstracts is made possible by studies completed after the initial November 15, 2017 abstract submission deadline. They are intended to represent the very latest development in transplantation science. These abstracts will be reviewed in a very finite period by a special review board, and accepted with the same stringent criteria as the Nov 2017 abstract submissions. The review criteria will be at par with the original call for abstracts in Nov 2017, but for late-breaking abstracts there will be a stronger focus on the criteria of "very latest development in the field of transplantation".

Call for Abstract Highlights

  • Submission deadline: November 15, 2017 Deadline Extended to December 6 (23:59 EST)
  • Notification of acceptance: February 15, 2018
  • Registration: presenters must be registered and paid by March 1, 2018; otherwise the abstract will be removed from the program
  • Rule of two: one presenter can only present 1 oral + 1 poster or 2 orals or 2 posters. Co-authors must be assigned as presenter if more abstracts were accepted.
  • Resubmission policy: abstracts that have been presented at other congresses can not be resubmitted unless if new research findings have become available
  • Accepted abstracts will be published in an online supplement to the Transplantation journal.

Abstract Themes and Topics

The organizers of the 27th International Congress of The Transplantation Society welcome the submission of abstracts for original contribution to the field in the following scientific themes (Click the + to expand the theme topics):

All abstract authors are asked to choose a scientific theme and topic during the submission process.

Anesthesia Management and Critical Care

Anesthesia Management and Critical Care

Basic Science and Translational Science

  • Antibody and sensitisation
  • B cell biology
  • Biomarkers, Immune Monitoring and Outcomes
  • Experimental and preclinical immunosuppression
  • Fibrogenesis and chronic graft injury
  • Haematopoietic chimerism and solid organ transplantation
  • Immune regulation and tolerance
  • Chemokines, Cytokines and Complement
  • Ischaemia-reperfusion injury
  • Mechanisms of allograft rejection
  • Microbiota
  • Mononuclear Phagocytes
  • Non-classical cell populations: NK, NKT, ILC and non-leucocytes
  • Omics' in transplantation: transcriptomics, genomics, epigenomics, metabolomics and proteomics
  • New source of organs - stem cells and xenografts
  • T cell biology
  • Tissue repair and stem cell therapies
  • Sex and Gender Issues

Cellular and Regenerative Therapies

  • Stem Cell Cellular Therapies
  • Regenerative Medicine
  • Hemopoetic Stem Cell
  • Bone Marrow


  • Bone diseases : All topics
  • Cardiovascular :All topics
  • Infection and rejection
  • Kidney complications: All topics
  • Malignancies
  • Metabolic syndrome after transplantation: All topics (except after liver transpolantation for NASH)
  • PTLD:  All Topics (except liver cancer recurrence)

Donation & Procurement

  • Deceased Organ Donation
  • Critical Care Management 
  • Public Policy / Regulation
  • Organ Utilization
  • Organ Procurement and Preservation
  • Living Organ Donation
  • Other Donation and Procurement Topics


  • All topics

Ethics, Community, Economics and DOI

  • Ethical Issues
  • Health Economics
  • Quality of Life and Psychosocial
  • Economics and Administration
  • Declaration of Istanbul

Heart and Lung

  • Heart all topics
  • Lung all topics


  • Antibody and sensitisation
  • Histocompatibility and Immunogenetics
  • Immune Monitoring and Biomarkers

Infectious Diseases

Infectious Diseases

Intestine & Multivisceral Transplantation

  • Intestine Multivisceral
  • Small Bowel Multivisceral
  • Other Intestine Topics


  • ABO incompatible
  • Access and Allocation
  • Acute Cellular Rejection
  • Acute Kidney Injury
  • Ageing and Kidney Transplantation
  • Antibody Mediated Rejection
  • Chronic Allograft Injury
  • Deceased Donor Issues (DCD, ECD/SCD)
  • Desensitization
  • Extracorporeal therapy
  • Histopathology
  • Immunopathology
  • Immunosuppression
  • Living donor transplants
  • Malignancies
  • Polyoma
  • Pre-transplant managment
  • Recipient Selelection
  • Recurrent disease
  • Other Kidney Topics


  • Access and Allocation
  • Acute and Chronic Rejection/ Liver Chronic Allograft Injury 
  • Anaesthia and Post-op Critical Care
  • Combined Liver Kidney Transplantation
  • Immunosuppression - Minimization - Avoidance Protocols
  • Liver Complications
  • Liver Immunosuppression
  • Liver Recipient Selection and management
  • Liver Tolerance
  • Living Donor
  • Malignancies Hepatocellular and Cholangiocarcinoma
  • MELD and Donor issues
  • Recurrent disease and retransplantation
  • Slipt Transplantation/Partial Grafts
  • Viral Hepatitis



Pancreas & Islet

  • Pancreas
  • Islet


Registry and statistical techniques

Sex and Gender in Transplantation

  • Sex and Transplant Outcome
  • Sex and Gender in Research and Clinical Care
  • Gender Issues in Transplantation

Transplant Immunosuppression

  • Avoidance Protocols
  • Complications of IS
  • Minimization and optimization
  • Personalized immunosuppression/ Pharmacogenomics/pharmacokinetics
  • Tolerance:  Clinical Studies
  • Transplant Immunosuppression  General
  • Tx Immunosuppression - Induction Therapy
  • Tx Immunosuppression - Novel Agents

Transplantation Nursing

  • Transplant Nursing
  • Treatment Non-Adherence

Vascularized Composite Allotransplantation

  • Novel Vascularised grafts
  • Vascularized Composite
  • Allograft Other VCA Topics



Abstract Submission Process

User Profile

Before submitting an abstract, the submitter must create a User Profile. After an abstract has been created, modifications can be made until the submission deadline.
The final deadline to submit the abstract is November 15, 2017 Deadline Extended to December 6 (23:59 EST). Abstracts received after this date cannot be accepted. The submitting author will receive notification of acceptance by February 15, 2018. Together with the confirmation of acceptance of your abstract, presenters will be requested to register for the congress. Deadline for presenter registration is March 1, 2018.

Important Dates

  • November 15, 2017
    Abstract submission deadline Deadline Extended to December 6 (23:59 EST)
  • February 15, 2018
    Communication to submitter on approved / rejected abstracts
  • March 1, 2018
    Deadline for presenter registration (early-bird deadline)

Choosing a Track Category

During the submission process, you will be asked to select one track category for your abstract. The track category is the general theme under which the abstract will be reviewed and later published in the congress materials (if accepted). The track category which best describes the subject of the abstract should be chosen first, then you will be asked to select a topic within the track.

Abstract Structure

Abstracts in all tracks should be structured chronologically in five sections: first Introduction; then Materials and Methods, Results, and Discussion (together, these three sections make up the paper's body); and finally, Conclusion.
  • The Introduction section clarifies the motivation for the work presented and prepares readers for the structure of the paper.
  • The Materials and Methods section provides sufficient detail for other scientists to reproduce the experiments presented in the paper. In some journals, this information is placed in an appendix, because it is not what most readers want to know first.
  • The Results and Discussion sections present and discuss the research results, respectively. They are often usefully combined into one section, however, because readers can seldom make sense of results alone without accompanying interpretation — they need to be told what the results mean.
  • The Conclusion section presents the outcome of the work by interpreting the findings at a higher level of abstraction than the Discussion and by relating these findings to the motivation stated in the Introduction. Explain the significance of your findings / outcomes and future implications of the results.

Abstract Guidelines

All abstracts must be submitted electronically through the Congress management system.
  • Abstracts will be accepted in English only.
  • There is no fee for submitting an abstract.
  • The abstract text body is limited to 3,000 characters including spaces. A maximum of four figures (in JPG, GIF or PNG with ideally 600 dpi) can be included. These will not count toward the word limit, nor will the information about authors, institutions and study groups. File size of 2 MB maximum for each figure.
  • Abstracts accepted for oral or poster presentation will be published online in a supplement to the Transplantation Journal. Abstracts not accepted for presentation will not be published. Abstracts will also be posted prior to the event on the Congress website.
  • Employees of Commercial Interests: TTS recognizes that employees of commercial interests are often involved in research and discovery and encourages these employees to submit abstracts to facilitate the flow of new information. Employees of commercial interests should submit abstracts when the content is limited to basic science research (e.g., pre-clinical research, drug discovery) or the processes/methodologies of research, themselves unrelated to a specific disease or compound/drug, and the abstract is not related to clinical applications of the research/discovery or clinical recommendations concerning the business lines or products of their employer.
  • Abstracts from employees of commercial interests that are selected for oral or poster presentation will be subject to an additional rigorous review to guard against presentation of content that is related to clinical recommendations concerning the business lines or products of the employer.
  • Ensure that all co-authors approve of the abstract submission, publication, and potential presentation. Abstracts cannot be changed or withdrawn after November 15, 2017 Deadline Extended to December 6 (23:59 EST).
  • Disclosure: abstract submitter and presenter are required to disclose any conflict of interest upon acceptance and on the first slide of presentation.
  • To be eligible to submit an abstract, you must disclose that the authors/ scientists have not violated any aspect of the Declaration of Istanbul (DOI) ethics' statement and that this research conforms with the ethical statements noted.
  • Presenter must confirm and register to the Congress by March 1, 2018, otherwise the abstract will not be published and will be removed from the program.

Policies for abstract submission

Copyright Policy

Abstracts should not include libelous or defamatory content. Material presented in abstracts should not violate any copyright laws. If figures/graphics/images have been taken from sources not copyrighted by the author, it is the author’s sole responsibility to secure the rights from the copyright holder in writing to reproduce those figures/graphics/images for both worldwide print and web publication. All reproduction costs charged by the copyright holder must be borne by the author.

Resubmission Policy

An abstract that has been previously published or presented at a national, regional or international meeting can only be submitted provided that there are new methods, findings, updated information or other valid reasons for submitting.


TTS regard plagiarism as serious professional misconduct. All abstracts are screened for plagiarism and when identified, the abstract and any other abstracts submitted by the same author are rejected. In addition, the submitting author’s profile and scholarship application, in the case one has been submitted, will also be cancelled.

Organ Trafficking and Tourism Ethics Compliance

To be eligible to submit and abstract, you must disclose that the author(s)/ scientist(s) have not violated any aspect of the following Ethics Statement:

Abstract review and selection process

Abstract Review

  • All submitted abstracts will go through a blinded peer-review process carried out by an international review committee.
  • All abstracts will be reviewed (blinded) by at least three international referees, selected by the Organizing Committee.
  • Abstracts which do not meet the focus of the topic category as requested by the authors will be reassigned to another category.
  • Scores assigned by all reviewers are averaged. The cut-off average score for acceptance is based on available oral and poster presentations. Rejections are further evaluated by the scientific program committee.
  • Poster and oral presentations are viewed as equally important components of the TTS Congress. Abstracts assigned to an oral presentation should stimulate discussion. The audience should also benefit from questions and answers following the presentation.

Format of presentation

You may opt to submit your abstract to be considered for an oral presentation, poster presentation, or either (at the committee’s discretion). If your abstract is accepted as an “oral”, it can be assigned to a full oral presentation, a shorter mini-oral or an interactive campfire discussion.

Notification of Acceptance or Rejection to Corresponding Author

Notification of acceptance or rejection will be sent to the submitting (corresponding) author by February 15, 2018. Please note that only the corresponding author will receive mail concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract.

Rule of Two

Each presenting author may present a maximum of two abstracts at the congress: two orals or two posters or one oral and one poster. The number of submissions is however not limited. Should an author have more than two abstracts accepted, a co-author must be named as presenting author for one or more abstracts. Should an author have more than two abstracts accepted for oral or poster presentation, a co-author must be named as presenting author for one or more abstracts. All presenting authors must register and attend the congress.

TTS Office Information

27th International Congress of The Transplantation Society
c/o The Transplantation Society
505 Blvd. René-Lévesque West, Suite 1401
Montreal, QC, H2Z 1A8, Canada
T. +1.514.874.1717; F. +1.514.874.1716

Join our Mailing List